Updates from ASH in Later Line Multiple Myeloma Management
ASH 2023 Insights: "KarMMa-3 Trial - Effects of Ide-Cel vs. Standard Regimens on HR-QOL in Patients With R/R MM Who Had Received 2-4 Prior Regimens"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Michel Delforge
By
Insights from 2023 ASH Annual Meeting
FEATURING
Michel Delforge
Login to view comments.
Click here to Login
